Project 3: Dissecting p53 Action in a Mouse Lymphoma Model Scott Lowe, Ph.D. p53 is a potent tumor suppressor that limits cancer development and contributes to the anti-tumor effects of certain cytotoxic agents. Accordingly, p53 mutations are associated with aggressive cancers, poor patient prognosis and, in some cases, therapy resistance. Our project studies the p53 network using the Ep-myc transgenic mouse, a well characterized model of B cell lymphoma in which p53 profoundly impacts tumorigenesis and treatment outcome. We previously used the E?mu?-myc system to study how p53 loss promotes tumor development and drug resistance, and to explore the relationship between cancer genotype, tumor progression, tumor maintenance, and treatment sensitivity. These studies produced new insights into p53 regulation and effector mechanisms in diverse contexts where it limits proliferation. They also established that p53 loss is required for tumor maintenance and that translational control of cell survival is a druggable mediator of oncogenesis. To facilitate our goals, we developed methods to genetically manipulate E?mu?-myc lymphomas, enabling the rapid and cost-effective production of mice harboring tumors with diverse genotypes. We also incorporated small animal imaging methods to track lymphoma progression and response, and stable and inducible RNAi technology to fine tune and study loss of function phenotypes. Moving forward, we seek to further explore the interplay between cancer genetics and cancer therapy in the E?mu?-myc system in order to produce a more complete picture of the p53 network and its action in vivo. We also wish to understand in detail how p53 mutations impact tumor behavior, and identify new therapeutic targets based on the vulnerabilities they create. We will perform focused RNAi screens to identify new modulators of p53 action relevant to suppressing tumorigenesis and/or modulating therapy response, test the hypothesis that the deletions on chromosome 17p influence cancer biology beyond simply inactivating p53, and identify and characterize drug targets that interact with the p53 tumor suppressor network. Our approach uses genomic data from human lymphoma to inform function studies in mice, and implements a suite of new animal modeling and genetic tools that are time and cost effective.
Successful completion of these studies will functionalize genetic changes that occur in human lymphoma and determine how they impact p53 action and/or influence disease behavior. They may also identify new therapeutic targets for treating p53 mutant cancers, which are often aggressive and more refractory to conventional therapies.
|Miething, Cornelius; Scuoppo, Claudio; Bosbach, Benedikt et al. (2014) PTEN action in leukaemia dictated by the tissue microenvironment. Nature 510:402-6|
|Jia, A Y; Castillo-Martin, M; Bonal, D M et al. (2014) MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9. Br J Cancer 110:2945-54|
|Barber, Alison G; Castillo-Martin, Mireia; Bonal, Dennis M et al. (2014) Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer. PLoS One 9:e98786|
|Chen, Chong; Liu, Yu; Rappaport, Amy R et al. (2014) MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 25:652-65|
|Jia, Angela Y; Castillo-Martin, Mireia; Domingo-Domenech, Josep et al. (2013) A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. Am J Pathol 182:1171-9|
|Mills, John R; Malina, Abba; Lee, Teresa et al. (2013) RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an E?-myc/Bcl-2 mouse model. Blood 121:3402-12|
|Freed-Pastor, William A; Mizuno, Hideaki; Zhao, Xi et al. (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148:244-58|
|Shen, Tian Huai; Gladoun, Nataliya; Castillo-Martin, Mireia et al. (2012) A BAC-based transgenic mouse specifically expresses an inducible Cre in the urothelium. PLoS One 7:e35243|
|Karni-Schmidt, Orit; Castillo-Martin, Mireia; Shen, Tian Huai et al. (2011) Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 178:1350-60|
|Wosnitzer, Matthew S; Domingo-Domenech, Josep; Castillo-Martin, Mireia et al. (2011) Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. J Urol 186:2094-100|
Showing the most recent 10 out of 68 publications